| pubmed-article:19946939 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19946939 | lifeskim:mentions | umls-concept:C1457887 | lld:lifeskim |
| pubmed-article:19946939 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:19946939 | lifeskim:mentions | umls-concept:C0036341 | lld:lifeskim |
| pubmed-article:19946939 | lifeskim:mentions | umls-concept:C0338656 | lld:lifeskim |
| pubmed-article:19946939 | lifeskim:mentions | umls-concept:C0025691 | lld:lifeskim |
| pubmed-article:19946939 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:19946939 | lifeskim:mentions | umls-concept:C0205160 | lld:lifeskim |
| pubmed-article:19946939 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:19946939 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:19946939 | pubmed:dateCreated | 2009-12-3 | lld:pubmed |
| pubmed-article:19946939 | pubmed:abstractText | Schizophrenic patients demonstrate a variety of cognitive deficits, including attention, executive functions, and working memory, even in the early stage of disease. In the present study, we examined the association between blood levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), or brain-derived neurotrophic factor (BDNF) and scores on the Wisconsin Card Sorting Test (WCST) in patients with early-stage schizophrenia. We also investigated the association between frontal GABA levels using 1H-magnetic resonance spectroscopy (MRS) at 3T and scores on the WCST in the same patients. Blood levels of BDNF and catecholamine metabolites and brain GABA levels using 1H-MRS were measured in 18 schizophrenic patients (nine males, nine females; age range 13-52 year). A significantly positive correlation was observed between plasma MHPG levels and %PEM (rho = -0.686, p = 0.0047). A trend toward negative correlation was found between frontal lobe GABA levels and the per cent of preservation error (%PEM) in the early stage of schizophrenia (rho = -0.420, p = 0.0836). These results suggest that noradrenergic neurons might be involved in neuropsychological functions in early-stage of schizophrenia. | lld:pubmed |
| pubmed-article:19946939 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19946939 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19946939 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19946939 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19946939 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19946939 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19946939 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19946939 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19946939 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19946939 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19946939 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:19946939 | pubmed:issn | 1099-1077 | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:HayashiKenjiK | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:YoshimuraReij... | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:UedaNobuhisaN | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:NakamuraJunJ | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:KorogiYukunor... | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:KakedaShingoS | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:MoriyaJunjiJ | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:HoriHikaruH | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:Ikenouchi-Sug... | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:Umene-NakanoW... | lld:pubmed |
| pubmed-article:19946939 | pubmed:author | pubmed-author:GotoNaokiN | lld:pubmed |
| pubmed-article:19946939 | pubmed:copyrightInfo | Copyright (c) 2009 John Wiley & Sons, Ltd. | lld:pubmed |
| pubmed-article:19946939 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19946939 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:19946939 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19946939 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19946939 | pubmed:pagination | 639-45 | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:meshHeading | pubmed-meshheading:19946939... | lld:pubmed |
| pubmed-article:19946939 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19946939 | pubmed:articleTitle | Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. | lld:pubmed |
| pubmed-article:19946939 | pubmed:affiliation | Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Japan. | lld:pubmed |
| pubmed-article:19946939 | pubmed:publicationType | Journal Article | lld:pubmed |
